Valor202020212022202320242025TTMGastos comerciales, generales y administrativos525.36 M584.47 M603.95 M579.17 M564.36 M583.67 M—Investigación y desarrollo149.07 M189.96 M189.86 M198.51 M193.49 M187.52 M—Beneficio operativo386.43 M630.08 M531.46 M409.94 M97.71 M465.85 M-397.68 MTotal de ingresos no operativos53.04 M-4.25 M-18.86 M19.87 M23.44 M24.41 M—Gastos por intereses, netos de intereses capitalizados71.32 M54.48 M58.36 M53.41 M86.44 M66.86 M—Ingresos no operativos, una vez deducidos los gastos por intereses-132.6 M-99.4 M-83.96 M-27.83 M-62.27 M-35.79 M—Ingresos/gastos extraordinarios114.33 M40.67 M6.74 M-5.71 M-739 K-6.65 M—Beneficio antes de impuestos439.47 M625.83 M512.6 M429.81 M121.15 M490.26 M1.55 BParticipación en los beneficios5.02 M11.99 M3.76 M4.16 M5.72 M4.4 M—Impuestos80.28 M113.23 M89.39 M88.51 M37.56 M65.39 M152.24 MParticipación minoritaria———————Otros ingresos/gastos después de impuestos-11.7 M-5.62 M-22.73 M-7.62 M-8.39 M-13.11 M—Beneficio neto antes de actividades interrumpidas359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BOperaciones suspendidas———————Beneficio neto359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BAjuste por dilución———————Dividendos de las acciones preferentes———————Beneficio neto diluido atribuible a los accionistas359.19 M512.6 M423.21 M341.3 M83.59 M424.88 M1.4 BBeneficio básico por acción1.662.391.971.540.381.96—Beneficio por acción diluido1.622.341.951.520.371.946.36Número medio de acciones ordinarias215.42 M215 M214.62 M221.81 M222.62 M217.22 M876.26 MAcciones diluidas220.88 M218.82 M217.03 M224.21 M224.72 M218.88 M884.84 MEBITDA527.95 M792.16 M679.18 M562.87 M258.38 M626 M—EBIT322.93 M577.23 M470.79 M357.53 M55.12 M432.25 M—Costo de los ingresos637.63 M802.99 M762.53 M731.63 M1.01 B790.5 M—Otros costes de producción574.47 M733.72 M696.47 M667.42 M952.32 M735.27 M—Amortización y depreciación (flujo de caja)205.01 M214.93 M208.4 M205.34 M203.27 M193.75 M342.68 M
Qiagen N.V
QIAGEN N.V. is a German-founded multinational provider of sample and assay technologies for molecular diagnostics, applied testing, academic research, and pharmaceutical research. The company operates in more than 35 offices in over 25 countries. QIAGEN N.V., the global corporate headquarter of the QIAGEN group, is located in Venlo, The Netherlands. The main operative headquarters are located in Hilden, Germany. European, American, Chinese, and Asian-Pacific regional headquarters are located respectively in Hilden, Germany; Germantown, Maryland, United States; Shanghai, China; and Singapore. QIAGEN's shares are listed at the NYSE and at the Frankfurt Stock Exchange in the Prime Standard. Thierry Bernard is the company's Chief Executive Officer.